Page last updated: 2024-10-24

cellular response to nitroglycerin

Definition

Target type: biologicalprocess

Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a nitroglycerin stimulus. [GO_REF:0000071, GOC:TermGenie, PMID:25626975]

Cellular response to nitroglycerin is a complex process involving multiple signaling pathways and physiological adaptations. Nitroglycerin, a potent vasodilator, is metabolized to nitric oxide (NO) within the smooth muscle cells of blood vessels. NO activates soluble guanylyl cyclase, leading to an increase in cyclic guanosine monophosphate (cGMP) levels. Elevated cGMP activates protein kinase G (PKG), which phosphorylates various downstream targets involved in smooth muscle relaxation. This phosphorylation leads to the dephosphorylation of myosin light chain, resulting in the relaxation of vascular smooth muscle and subsequent vasodilation. Vasodilation reduces preload and afterload on the heart, leading to decreased myocardial oxygen demand. Additionally, nitroglycerin can also activate potassium channels, further contributing to vasodilation and a decrease in blood pressure. The overall effect of nitroglycerin is a reduction in cardiac workload, which can be beneficial in conditions such as angina pectoris. Furthermore, nitroglycerin can also activate other signaling pathways, including the mitogen-activated protein kinase (MAPK) and PI3K/Akt pathways. These pathways are involved in various cellular processes, such as cell survival, proliferation, and angiogenesis. In addition to its direct effects on vascular smooth muscle, nitroglycerin can also modulate the activity of various inflammatory mediators. This effect can contribute to the anti-inflammatory properties of nitroglycerin. The cellular response to nitroglycerin is a multifaceted process involving a complex interplay of signaling pathways and physiological adaptations. Understanding these mechanisms is crucial for optimizing the therapeutic use of nitroglycerin and developing novel strategies for treating cardiovascular diseases.'
"

Proteins (1)

ProteinDefinitionTaxonomy
Heat shock factor protein 1A heat shock factor protein 1 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q00613]Homo sapiens (human)

Compounds (11)

CompoundDefinitionClassesRoles
zm 336372N-(5-(3-dimethylaminobenzamido)-2-methylphenyl)-4-hydroxybenzamide: an inhibitor of c-Raf; activates Raf-1; structure in first sourcebenzamides
celastrolmonocarboxylic acid;
pentacyclic triterpenoid
anti-inflammatory drug;
antineoplastic agent;
antioxidant;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
Hsp90 inhibitor;
metabolite
quercetin7-hydroxyflavonol;
pentahydroxyflavone
antibacterial agent;
antineoplastic agent;
antioxidant;
Aurora kinase inhibitor;
chelator;
EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor;
geroprotector;
phytoestrogen;
plant metabolite;
protein kinase inhibitor;
radical scavenger
chir-265aromatic ether
az-628AZ-628: a multikinase inhibitor; structure in first sourcebenzamides
GDC-0879indanes;
ketoxime;
primary alcohol;
pyrazoles;
pyridines
antineoplastic agent;
B-Raf inhibitor
plx4032aromatic ketone;
difluorobenzene;
monochlorobenzenes;
pyrrolopyridine;
sulfonamide
antineoplastic agent;
B-Raf inhibitor
dabrafenib1,3-thiazoles;
aminopyrimidine;
organofluorine compound;
sulfonamide
anticoronaviral agent;
antineoplastic agent;
B-Raf inhibitor
tak-632TAK-632 : A member of the class of benzothiazoles that is 1,3-benzothiazole substituted by (cyclopropanecarbonyl)amino, 4-fluoro-3-{2-[3-(trifluoromethyl)phenyl]acetamido}phenoxy, and cyano groups at positions 2, 6 and 7, respectively. It is a potent pan-RAF inhibitor with IC50 of 1.4, 2.4 and 8.3 nM for CRAF, BRAF(V600E), BRAF(WT), respectively.(trifluoromethyl)benzenes;
aromatic ether;
benzothiazoles;
cyclopropylcarboxamide;
monofluorobenzenes;
nitrile;
secondary carboxamide
antineoplastic agent;
apoptosis inducer;
B-Raf inhibitor;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
necroptosis inhibitor
dinaciclibpyrazolopyrimidine
n2-(1h-indazole-5-yl)-n6-methyl-3-nitropyridine-2,6-diamineKRIBB11 : A member of the class of indazoles that is 1H-indazole substituted by a [6-(methylamino)-3-nitropyridin-2-yl]amino group at position 5. It is an inhibitor of heat shock factor 1 (IC50 = 1.2muM) and suppresses tumour growth in mouse xenograft models.

N2-(1H-indazole-5-yl)-N6-methyl-3-nitropyridine-2,6-diamine: a heat shock factor 1 antagonist; structure in first source